TaiMed Biologics (ROCO:4147) Cyclically Adjusted Revenue per Share: NT$2.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4147 TaiMed Biologics Inc ROCO:4147
63 GF Score
Price NT$56.20
GF Value NT$80.43
Valuation Significantly Undervalued
View Full Analysis

What is TaiMed Biologics Cyclically Adjusted Revenue per Share?

TaiMed Biologics ROCO:4147 -0.53% 63 Cyclically Adjusted Revenue per Share is NT$2.06 as of Mar. 2026. GuruFocus rates ROCO:4147 with a GF Score™ of 63/100 and a GF Value™ of NT$80.43 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

TaiMed Biologics's adjusted revenue per share for the three months ended in Mar. 2026 was NT$0.608. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$2.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TaiMed Biologics's average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of TaiMed Biologics was 7.30% per year. The lowest was 4.70% per year. And the median was 6.00% per year.

As of today (2026-07-31), TaiMed Biologics's current stock price is NT$56.20. TaiMed Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$2.06. TaiMed Biologics's Cyclically Adjusted PS Ratio of today is 27.28.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TaiMed Biologics was 75.22. The lowest was 23.45. And the median was 43.06.


TaiMed Biologics  (ROCO:4147) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TaiMed Biologics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=56.20/2.06
=27.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TaiMed Biologics was 75.22. The lowest was 23.45. And the median was 43.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


TaiMed Biologics Cyclically Adjusted Revenue per Share Related Terms


TaiMed Biologics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Cyclically Adjusted Revenue per Share Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 1.71 1.78 1.88 1.96

TaiMed Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 1.94 1.96 1.96 2.06

ROCO:4147 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, TaiMed Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Cyclically Adjusted PS Ratio falls into.


ROCO:4147
63GF Score
TaiMed Biologics Inc ROCO:4147
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TaiMed Biologics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.608/330.2130*330.2130
=0.608

Current CPI (Mar. 2026) = 330.2130.

TaiMed Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.002 241.018 0.003
201609 0.003 241.428 0.004
201612 0.002 241.432 0.003
201703 0.005 243.801 0.007
201706 0.010 244.955 0.013
201709 0.010 246.819 0.013
201712 0.009 246.524 0.012
201803 0.000 249.554 0.000
201806 0.149 251.989 0.195
201809 0.344 252.439 0.450
201812 0.450 251.233 0.591
201903 0.503 254.202 0.653
201906 0.605 256.143 0.780
201909 0.828 256.759 1.065
201912 0.815 256.974 1.047
202003 0.935 258.115 1.196
202006 0.696 257.797 0.892
202009 0.579 260.280 0.735
202012 0.595 260.474 0.754
202103 0.357 264.877 0.445
202106 0.601 271.696 0.730
202109 0.358 274.310 0.431
202112 0.296 278.802 0.351
202203 0.159 287.504 0.183
202206 0.387 296.311 0.431
202209 0.370 296.808 0.412
202212 1.275 296.797 1.419
202303 0.280 301.836 0.306
202306 0.414 305.109 0.448
202309 0.536 307.789 0.575
202312 0.625 306.746 0.673
202403 0.706 312.332 0.746
202406 0.534 314.175 0.561
202409 0.513 315.301 0.537
202412 0.534 315.605 0.559
202503 0.645 319.799 0.666
202506 0.509 322.561 0.521
202509 0.528 324.800 0.537
202512 0.549 324.054 0.559
202603 0.608 330.213 0.608

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$2.06 mean?
TaiMed Biologics (ROCO:4147) has a Cyclically Adjusted Revenue per Share of NT$2.06 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TaiMed Biologics and its competitors.
Is TaiMed Biologics' Cyclically Adjusted Revenue per Share too high?
TaiMed Biologics' current Cyclically Adjusted Revenue per Share is NT$2.06. Overall, TaiMed Biologics has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
TaiMed Biologics' Cyclically Adjusted Revenue per Share of NT$2.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current Cyclically Adjusted Revenue per Share is NT$2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$80.43, compared to a current price of NT$56.20 — trading 30.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$2.06. TaiMed Biologics' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Cyclically Adjusted Revenue per Share is NT$2.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$56.20 is trading 30.1% below its estimated GF Value™ of NT$80.43. GuruFocus considers TaiMed Biologics to be Significantly Undervalued.

Key valuation signals for ROCO:4147:

  • Cyclically Adjusted Revenue per Share: NT$2.06
  • GF Value™: NT$80.43 vs. price of NT$56.20 (30.1% below fair value)
  • GF Score™: 63/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
63GF Score

Get the complete analysis for ROCO:4147

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.20
Price
NT$80.43
GF Value